Drug
MIK-665 clinical trials
Also written MIK665 and S64315.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 3
Institut de Recherches Internationales Servier (3) · Novartis Pharmaceuticals (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MIK-665 is read from its arms, and is right about nine times in ten.
Testing it · 5
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedPhase 1Novartis PharmaceuticalsNCT04702425Written as MIK665
- Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid LeukaemiaCompletedPhase 1/2Institut de Recherches Internationales ServierNCT04629443Written as S 64315 (also referred as MIK665) and azacitidine
- Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.CompletedPhase 1Institut de Recherches Internationales ServierNCT03672695Written as S 64315 (also referred as MIK665) and venetoclax
- Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedPhase 1Institut de Recherches Internationales ServierNCT02979366Written as S64315 once a week
- Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedPhase 1Novartis PharmaceuticalsNCT02992483Written as MIK665
Codes
What other systems call MIK-665 · ClinicalTrials.gg INT015562
- UNII (FDA) 801XYWHNOSMIK-665One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 801XYWHNOS | MIK-665 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.